Yang Yuening, Wang Haolei, Xue Qianqian, Peng Wenbei, Zhou Qiong
Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China.
Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China.
J Ethnopharmacol. 2025 Apr 25;346:119636. doi: 10.1016/j.jep.2025.119636. Epub 2025 Mar 20.
With the rise of immunotherapy, the treatment approach for non-small cell lung cancer (NSCLC) has undergone revolutionary changes. However, the prognosis for NSCLC patients has not been significantly improved due to the development of acquired drug resistance. Therefore, there is an urgent need to develop new and more effective drugs for treating NSCLC or improving tumor treatment resistance. Traditional Chinese medicine (TCM) has been gradually incorporated into the combined treatment of NSCLC. Its active components (also known as natural products) exhibit novel structures, multi-target effects, diverse pathways, minimal toxicity, and varied biological activities, which play a therapeutic role in various diseases. Thus, natural products hold great potential for future clinical applications.
Screening main traditional plants widely used in NSCLC and their derived natural products, as well as exploring the mechanisms by which these natural products act on NSCLC-particularly focusing on their applications-can provide valuable insights for the development of therapeutic drugs targeting NSCLC.
A comprehensive, computerized literature search was conducted in PubMed, Embase, Web of Science, Cochrane Library, CNKI Scholar, the American Chemical Abstracts, and Wanfang Database up to June 2024, using the following keywords: "traditional Chinese medicine", "herbal medicine", "medicinal plants", and "herbal", paired with terms such as "non-small cell lung cancer", "therapy", "natural products", and "active ingredient".
Summarizing current research findings, we discovered eleven medicinal plants containing a total of fourteen natural products. Natural products have a significant impact on tumor progression in NSCLC, including apotosis, autophagy, pyrotosis, cell-cycle arrest and metasis. Moreover, natural products can modulate the activities of various immune cells and reshape the immune microenvironment. Combined with conventional cancer treatments, natural products demonstrate promising therapeutic effects and effectively reverse drug resistance. Furthermore,the use of nano-drug delivery systems to address limitations associated with natural products.
This review summarizes eleven medicinal plants containing a total of fourteen natural products that can enhance NSCLC treatment and indicates their action mechanisms. Furthermore, we also discuss limitations of natural products and explore the use of nano-drug delivery systems to address limitations associated with natural products.
随着免疫疗法的兴起，非小细胞肺癌（NSCLC）的治疗方法发生了革命性变化。然而，由于获得性耐药的出现，NSCLC患者的预后并未得到显著改善。因此，迫切需要开发新的、更有效的药物来治疗NSCLC或提高肿瘤治疗耐药性。传统中药（TCM）已逐渐纳入NSCLC的联合治疗中。其活性成分（也称为天然产物）具有新颖的结构、多靶点作用、多样的途径、最小的毒性和多种生物活性，在各种疾病中发挥治疗作用。因此，天然产物在未来临床应用中具有巨大潜力。
筛选广泛用于NSCLC的主要传统植物及其衍生的天然产物，并探索这些天然产物作用于NSCLC的机制——特别关注它们的应用——可为开发针对NSCLC的治疗药物提供有价值的见解。
截至2024年6月，在PubMed、Embase、Web of Science、Cochrane Library、中国知网 Scholar、美国化学文摘和万方数据库中进行了全面的计算机文献检索，使用以下关键词：“传统中药”、“草药”、“药用植物”和“草本植物”，并与“非小细胞肺癌”、“治疗”、“天然产物”和“活性成分”等术语配对。
总结当前研究结果，我们发现了11种药用植物，共含有14种天然产物。天然产物对NSCLC的肿瘤进展有显著影响，包括凋亡、自噬、焦亡、细胞周期阻滞和转移。此外，天然产物可以调节各种免疫细胞的活性并重塑免疫微环境。与传统癌症治疗相结合，天然产物显示出有前景的治疗效果，并能有效逆转耐药性。此外，使用纳米药物递送系统来解决与天然产物相关的局限性。
本综述总结了11种药用植物，共含有14种可增强NSCLC治疗效果的天然产物，并指出了它们的作用机制。此外，我们还讨论了天然产物的局限性，并探索使用纳米药物递送系统来解决与天然产物相关的局限性。
